HC Wainwright Begins Coverage on Denali Therapeutics (NASDAQ:DNLI)

HC Wainwright began coverage on shares of Denali Therapeutics (NASDAQ:DNLI) in a research report issued to clients and investors on Wednesday, Zacks reports. The brokerage set a “strong-buy” rating on the stock. HC Wainwright also issued estimates for Denali Therapeutics’ Q4 2026 earnings at ($0.62) EPS, FY2026 earnings at ($1.61) EPS, Q1 2027 earnings at ($0.60) EPS, Q2 2027 earnings at ($0.59) EPS, Q3 2027 earnings at ($0.57) EPS, Q4 2027 earnings at ($0.53) EPS, FY2027 earnings at ($2.38) EPS, FY2028 earnings at ($1.77) EPS, FY2029 earnings at ($1.51) EPS and FY2030 earnings at ($0.14) EPS.

Other analysts have also recently issued reports about the stock. B. Riley Financial upped their price target on shares of Denali Therapeutics from $30.00 to $35.00 and gave the company a “buy” rating in a report on Tuesday, August 25th. JPMorgan Chase & Co. began coverage on shares of Denali Therapeutics in a report on Monday, July 13th. They set an “overweight” rating and a $29.00 price objective for the company. UBS Group raised their price objective on shares of Denali Therapeutics from $25.00 to $34.00 and gave the stock a “buy” rating in a report on Friday, August 7th. Wedbush boosted their target price on shares of Denali Therapeutics from $23.00 to $24.00 and gave the stock an “outperform” rating in a research report on Wednesday. Finally, Robert W. Baird set a $34.00 target price on shares of Denali Therapeutics in a research note on Friday, August 7th. One investment analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $36.15.

Denali Therapeutics Stock Performance

Shares of DNLI opened at $19.72 on Wednesday. The firm has a market cap of $3.16 billion, a price-to-earnings ratio of -11.40 and a beta of 1.08. The company has a quick ratio of 8.32, a current ratio of 6.21 and a debt-to-equity ratio of 0.01. The business’s 50 day moving average is $20.25 and its two-hundred day moving average is $21.26. Denali Therapeutics has a 52-week low of $13.75 and a 52-week high of $27.30.

Denali Therapeutics (NASDAQ:DNLI) last released its quarterly earnings results on Tuesday, November 3rd. The company reported $0.37 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.64. The company had revenue of $17.78 million for the quarter, compared to analyst estimates of $12.67 million. During the same period in the previous year, the business posted ($0.74) EPS. Analysts forecast that Denali Therapeutics will post -2.70 EPS for the current fiscal year.

Insider Activity at Denali Therapeutics

In other news, insider Alexander O. Schuth sold 2,857 shares of Denali Therapeutics stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $25.07, for a total value of $71,624.99. Following the completion of the transaction, the insider owned 281,763 shares in the company, valued at approximately $7,063,798.41. This trade represents a 1.00% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 9.70% of the company’s stock.

Institutional Investors Weigh In On Denali Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the company. GAMMA Investing LLC boosted its holdings in Denali Therapeutics by 44.4% in the third quarter. GAMMA Investing LLC now owns 2,236 shares of the company’s stock worth $46,000 after purchasing an additional 687 shares during the period. PNC Financial Services Group Inc. increased its stake in Denali Therapeutics by 8.7% during the first quarter. PNC Financial Services Group Inc. now owns 9,220 shares of the company’s stock valued at $177,000 after purchasing an additional 739 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new stake in shares of Denali Therapeutics during the second quarter worth $26,000. Global Retirement Partners LLC acquired a new stake in shares of Denali Therapeutics during the second quarter worth $28,000. Finally, Nykredit A S acquired a new stake in shares of Denali Therapeutics during the second quarter worth $38,000. 92.92% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about Denali Therapeutics

Here are the key news stories impacting Denali Therapeutics this week:

• Positive Sentiment: Denali’s Q3 earnings beat expectations, while Avlayah sales reportedly rose nearly fivefold and reimbursement coverage expanded. The company also has several pipeline catalysts approaching, giving investors reasons to focus on future growth. Zacks article
• Positive Sentiment: Morgan Stanley raised its price target to $42 and maintained an Overweight rating; Wedbush also lifted its target, to $24, with an Outperform rating. These target increases suggest those analysts see potential upside. Analyst target report
• Neutral Sentiment: HC Wainwright’s estimates project ongoing losses in the coming years, including a $0.62-per-share loss in Q4 2026, but a narrower $0.14 loss in 2030. These are analyst forecasts, not company results, and indicate that a path toward profitability may take time.
• Negative Sentiment: Despite the earnings beat, investors may weigh Denali’s continuing expected losses and valuation against its commercial growth and pipeline prospects. Yahoo Finance article

About Denali Therapeutics

Denali Therapeutics Inc is a biopharmaceutical company focused on discovering and developing therapies for patients with neurodegenerative diseases. The company’s research programs target conditions including Parkinson’s disease, Alzheimer’s disease, amyotrophic lateral sclerosis, and lysosomal storage disorders.

Denali uses its blood-brain barrier transport technology, known as the Transport Vehicle platform, to design medicines intended to deliver therapeutic proteins and other biologic treatments into the central nervous system.